Author

K. Bowman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1 Organism:non-human primate· 1

Frequent Co-Authors

D. A. Lauffenburger· 2 shared G. Alter· 2 shared M. J. Gorman· 2 shared A. D. Portnoff· 1 shared A. M. Greene· 1 shared A. S. Menon· 1 shared A. Schmidt· 1 shared A. Zhu· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. A. Lauffenburger

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19

P. Kaplonek, C. Wang, Y. Bartsch, S. Fischinger, M. J. Gorman, K. Bowman, J. Kang, D. Dayal, P. Martin, R. Nowak, C.-L. Hsieh, J. Feldman, B. Juelg, E. Nilles, E. R. Musk, , G. Alter

The paper profiles early humoral immune responses in COVID-19 patients, finding that survivors show rapid SARS-CoV-2-specific immunity linked to pre-existing OC43 immunity, while non-survivors have delayed and blunted responses.

bioRxiv · May 11, 2021 · PreprintImmunology

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

M. J. Gorman, N. Patel, M. Guebre-Xabier, A. Zhu, C. Atyeo, K. Pullen, C. Loos, Y. Goez-Gazi, R. Carrion, J.-H. Tian, D. Yuan, K. Bowman, B. Zhou, S. Maciejewski, M. McGrath, , G. Alter

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

bioRxiv · Feb 5, 2021 · PreprintImmunology